Key facts
- This page summarizes Warren Karl Volles's Form 3 filing for Biohaven Ltd. (BHVN).
- 0 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 17 Jul 2026, 18:00.
Warren Karl Volles - 09 Jul 2026 Form 3 Insider Report for Biohaven Ltd. (BHVN)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- BHVN
- Reported as of
- 09 Jul 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ George Clark, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Warren Karl Volles filed Form 3 for Biohaven Ltd. (BHVN) on 17 Jul 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002146037
Primary reporting owner
Volles Warren Karl
- Relationship
- Chief Legal Officer
- Address
- 215 CHURCH STREET, NEW HAVEN
- Signature
- /s/ George Clark, Attorney-in-Fact
- Signature date
- 17 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BHVN
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 248,212
- Date
- 09 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BHVN
holding
Derivative
Stock Options (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 300,000
- Exercise price
- $7.00
- Footnotes
- F2
BHVN
holding
Derivative
Stock Options (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 78,750
- Exercise price
- $29.49
- Footnotes
- F3
BHVN
holding
Derivative
Stock Options (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 95,250
- Exercise price
- $41.93
- Footnotes
- F4
BHVN
holding
Derivative
Stock Options (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 83,000
- Exercise price
- $38.64
- Footnotes
- F5
BHVN
holding
Derivative
Stock Options (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 175,000
- Exercise price
- $11.52
- Footnotes
- F6
BHVN
holding
Derivative
Restricted Share Unit Award
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 14,000
- Exercise price
- Footnotes
- F7, F8, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
This balance includes 742 shares, 1,086 shares, 2 shares, and 2,500 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2024, May 31, 2025, November 30, 2025, and May 31, 2026, respectively.
Footnote F2
The shares underlying this option became exercisable on and prior to October 3, 2025.
Footnote F3
The shares underlying this option became exercisable as to 59,063 of these shares on and prior to November 2, 2025, with the remainder vesting on November 2, 2026, subject to the Reporting Person's continued service with the Issuer at the vesting date.
Footnote F4
The shares underlying this option became exercisable as to 72,188 of these shares on and prior to January 2, 2026, with the remainder vesting on January 2, 2027, subject to the Reporting Person's continued service with the Issuer at the vesting date.
Footnote F5
The shares underlying this option became exercisable as to 41,500 of these shares on and prior to January 5, 2026, with the remainder vesting in two equal installments on January 5, 2027, and 2028, subject to the Reporting Person's continued service with the Issuer at each vesting date.
Footnote F6
The shares underlying this option became exercisable as to 43,750 of these shares on February 27, 2026, with the remainder vesting in three equal installments on February 27, 2027, 2028, and 2029, subject to the Reporting Person's continued service with the Issuer at each vesting date.
Footnote F7
The reporting person was granted 14,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027, and 2028, subject to the Reporting Person's continued service with the Issuer at each vesting date.
Footnote F8
Not applicable.
Footnote F9
Each restricted share unit represents the contingent right to receive one common share of the Issuer.
SEC remarks
Exhibit List: Exhibit 24: Power of attorney